NASDAQ:AERI - Aerie Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aerie Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $22.87 -1.24 (-5.14 %) (As of 01/17/2020 12:30 PM ET) Add Compare Today's Range$22.11Now: $22.87▼$24.0350-Day Range$18.35MA: $22.74▼$25.5252-Week Range$17.15Now: $22.87▼$50.10Volume31,907 shsAverage Volume835,509 shsMarket Capitalization$1.06 billionP/E RatioN/ADividend YieldN/ABeta0.53 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, retinal diseases, and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AERI Previous Symbol CUSIPN/A CIK1337553 Webhttp://www.aeriepharma.com/ Phone919-237-5300Debt Debt-to-Equity Ratio0.94 Current Ratio5.43 Quick Ratio5.23Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$24.18 million Price / Sales43.81 Cash FlowN/A Price / Cash FlowN/A Book Value$5.01 per share Price / Book4.56Profitability EPS (Most Recent Fiscal Year)($4.65) Net Income$-232,570,000.00 Net Margins-328.34% Return on Equity-77.63% Return on Assets-48.31%Miscellaneous Employees353 Outstanding Shares46,321,000Market Cap$1.06 billion Next Earnings Date2/24/2020 (Estimated) OptionableOptionable Receive AERI News and Ratings via Email Sign-up to receive the latest news and ratings for AERI and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:AERI Rates by TradingView Aerie Pharmaceuticals (NASDAQ:AERI) Frequently Asked Questions What is Aerie Pharmaceuticals' stock symbol? Aerie Pharmaceuticals trades on the NASDAQ under the ticker symbol "AERI." How were Aerie Pharmaceuticals' earnings last quarter? Aerie Pharmaceuticals Inc (NASDAQ:AERI) issued its earnings results on Wednesday, November, 6th. The company reported ($0.86) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.84) by $0.02. The business earned $18.54 million during the quarter, compared to analyst estimates of $17.59 million. Aerie Pharmaceuticals had a negative return on equity of 77.63% and a negative net margin of 328.34%. View Aerie Pharmaceuticals' Earnings History. When is Aerie Pharmaceuticals' next earnings date? Aerie Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, February 24th 2020. View Earnings Estimates for Aerie Pharmaceuticals. What price target have analysts set for AERI? 13 brokerages have issued 1-year price targets for Aerie Pharmaceuticals' shares. Their forecasts range from $25.00 to $56.00. On average, they expect Aerie Pharmaceuticals' share price to reach $40.77 in the next year. This suggests a possible upside of 78.3% from the stock's current price. View Analyst Price Targets for Aerie Pharmaceuticals. What is the consensus analysts' recommendation for Aerie Pharmaceuticals? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aerie Pharmaceuticals in the last year. There are currently 1 hold rating and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aerie Pharmaceuticals. What are Wall Street analysts saying about Aerie Pharmaceuticals stock? Here are some recent quotes from research analysts about Aerie Pharmaceuticals stock: 1. HC Wainwright analysts commented, "We recently lowered our 2019 revenue to just under $80M vs. prior guidance of $110-120M, and Aeri just lowered to $70-80M. While this looks far below consensus of $98M, we believe current expectation were more in the $85M range, thus guidance is not too far below that. Importantly, we believe the guidance is very achievable, and based only on what the company is already seeing internally in terms of orders, leading indicators and managed care progress, rather than on aggressive market-research based assumptions." (8/8/2019) 2. According to Zacks Investment Research, "The uptake of Aerie’s lead drug, Rhopressa, has been strong so far. The drug continues to gain traction with an increase in covered lives under various Medicare plans. The approval of the second drug, Rocklatan, a once-daily, quadruple-action fixed-dose combination of Rhopressa and Xalatan, has boosted the company’s portfolio and should propel sales in the coming quarters as glaucoma is one of the largest segments in the global ophthalmic market. We are also impressed with the company’s efforts to develop and boost pipeline. The company is evaluating possible uses of its proprietary portfolio of Rho Kinase inhibitors beyond glaucoma. Shares have outperformed the industry in the year so far. While the glaucoma market holds potential, Aerie faces stiff competition from existing players and new ones like Vyzulta, among others." (6/28/2019) 3. Mizuho analysts commented, "We adjusted our 1Q19 revenue estimate for Rhopressa down but maintain our FY2019 net revenue estimate at the high-end of guidance. We expect Rhopressa Scripts to pick up around June driven by higher anticipated formulary coverage (Medicare Part D going from ~40% currently to ~70%+ in May – guided by management)." (4/21/2019) Has Aerie Pharmaceuticals been receiving favorable news coverage? Headlines about AERI stock have been trending positive recently, InfoTrie Sentiment reports. The research firm scores the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Aerie Pharmaceuticals earned a daily sentiment score of 2.5 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the next several days. View News Stories for Aerie Pharmaceuticals. Are investors shorting Aerie Pharmaceuticals? Aerie Pharmaceuticals saw a decrease in short interest in the month of December. As of December 31st, there was short interest totalling 13,290,000 shares, a decrease of 9.6% from the December 15th total of 14,700,000 shares. Based on an average daily trading volume, of 1,130,000 shares, the short-interest ratio is currently 11.8 days. Approximately 35.2% of the company's shares are short sold. View Aerie Pharmaceuticals' Current Options Chain. Who are some of Aerie Pharmaceuticals' key competitors? Some companies that are related to Aerie Pharmaceuticals include Spark Therapeutics (ONCE), Ablynx (ABLYF), Adaptive Biotechnologies (ADPT), Crispr Therapeutics (CRSP), Allogene Therapeutics (ALLO), Iovance Biotherapeutics (IOVA), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Audentes Therapeutics (BOLD), Momenta Pharmaceuticals (MNTA), Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Regenxbio (RGNX), Editas Medicine (EDIT) and SpringWorks Therapeutics (SWTX). What other stocks do shareholders of Aerie Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aerie Pharmaceuticals investors own include Canopy Growth (CGC), NicOx (NICXF), Melinta Therapeutics (MLNT), Micron Technology (MU), NVIDIA (NVDA), Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Plug Power (PLUG) and Alibaba Group (BABA). Who are Aerie Pharmaceuticals' key executives? Aerie Pharmaceuticals' management team includes the folowing people: Dr. Vicente J. Anido Jr., CEO & Chairman (Age 66)Mr. Thomas A. Mitro, Pres & COO (Age 61)Dr. Casey C. Kopczynski, Co-Founder & Chief Scientific Officer (Age 58)Mr. Richard James Rubino CPA, CFO, Sec. & Treasurer (Age 61)Ms. Jessica Crespo CPA, Director of Accounting How do I buy shares of Aerie Pharmaceuticals? Shares of AERI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Aerie Pharmaceuticals' stock price today? One share of AERI stock can currently be purchased for approximately $22.87. How big of a company is Aerie Pharmaceuticals? Aerie Pharmaceuticals has a market capitalization of $1.06 billion and generates $24.18 million in revenue each year. The company earns $-232,570,000.00 in net income (profit) each year or ($4.65) on an earnings per share basis. Aerie Pharmaceuticals employs 353 workers across the globe.View Additional Information About Aerie Pharmaceuticals. What is Aerie Pharmaceuticals' official website? The official website for Aerie Pharmaceuticals is http://www.aeriepharma.com/. How can I contact Aerie Pharmaceuticals? Aerie Pharmaceuticals' mailing address is 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703. The company can be reached via phone at 919-237-5300 or via email at [email protected] MarketBeat Community Rating for Aerie Pharmaceuticals (NASDAQ AERI)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 724 (Vote Outperform)Underperform Votes: 469 (Vote Underperform)Total Votes: 1,193MarketBeat's community ratings are surveys of what our community members think about Aerie Pharmaceuticals and other stocks. Vote "Outperform" if you believe AERI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AERI will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/17/2020 by MarketBeat.com StaffFeatured Article: Closed-End Mutual Funds
